NovoCure Ltd (NovoCure) carries out the discovery, development and marketing of novel Tumor Treating Fields (TTF) delivery systems for the treatment of aggressive cancers of brain and abdomen. The company has two marketed products: Optune Lua and Optune Gio. For Optune Lua, the company obtained the US Food and Drug Administration’s (FDA) approval under Humanitarian Device Exemption (HDE) pathway for the treatment of malignant pleural mesothelioma (MPM) in combination with standard chemotherapies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

NovoCure's R&D initiatives focus on developing and growing their sales and marketing, patient support, and research and development teams to achieve commercial success for their products. The company is engaged in extensive preclinical and clinical testing to assess the safety and efficacy of their products and TTFields. The company is also involved in modifying its products to improve efficacy, reduce side effects, and enhance user experience. The R&D unit of NovoCure is located in Haifa, Israel. This unit is responsible for managing the company's research and development activities, including conducting preclinical and clinical studies and ensuring compliance with regulatory guidelines. In FY2025, the company spent US$224.5 million on its R&D activities, which as a percentage of revenue stood at 34.2%. NovoCure's intellectual property portfolio consists of several issued patents and pending patent applications worldwide.